Sarah V. Holt

898 total citations
15 papers, 676 citations indexed

About

Sarah V. Holt is a scholar working on Molecular Biology, Cell Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Sarah V. Holt has authored 15 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 4 papers in Cell Biology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Sarah V. Holt's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Cell death mechanisms and regulation (3 papers) and Cancer Mechanisms and Therapy (3 papers). Sarah V. Holt is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Cell death mechanisms and regulation (3 papers) and Cancer Mechanisms and Therapy (3 papers). Sarah V. Holt collaborates with scholars based in United Kingdom, United States and China. Sarah V. Holt's co-authors include Deema Hussein, Stephen S. Taylor, Victoria Johnson, Robert W. Wilkinson, Armelle Logié, Paul D. Smith, Barry R. Davies, Denis Alférez, Viki Allan and M. Vergnolle and has published in prestigious journals such as Cancer Research, Journal of Cell Science and British Journal of Cancer.

In The Last Decade

Sarah V. Holt

14 papers receiving 669 citations

Peers

Countries citing papers authored by Sarah V. Holt

Since Specialization

Citations

This map shows the geographic impact of Sarah V. Holt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah V. Holt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah V. Holt more than expected).

Fields of papers citing papers by Sarah V. Holt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah V. Holt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah V. Holt. The network helps show where Sarah V. Holt may publish in the future.

Co-authorship network of co-authors of Sarah V. Holt

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah V. Holt. A scholar is included among the top collaborators of Sarah V. Holt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah V. Holt. Sarah V. Holt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Abstract CT267: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors 2025 ·Cancer Research ·Susanna V. Ulahannan, Jason T. Henry, Kathleen N. Moore, Gerald S. Falchook, (unknown), Elisa Fontana, (unknown), (unknown), Helen Millward, Anitra Fielding, Sara Busacca, Emre Karakoç, Suraj Menon, Sarah V. Holt, Niall M.B. Martin, Graeme C.M. Smith, (unknown), Ian C. P. Smith, Bert H. O’Neil, Babar Bashir	0
2	Abstract LB520: A pharmacodynamic platform using liquid biopsy to support dose selection for the ATR inhibitor ART0380 (IACS-030380) 2022 ·Cancer Research ·Manish R. Patel, Kathleen N. Moore, (unknown), Jayesh B. Majithiya, (unknown), Helen Millward, Sarah V. Holt, Melissa M. Johnson	2
3	A pharmacokinetic–pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055 2017 ·British Journal of Pharmacology ·James Yates, Sarah V. Holt, Armelle Logié, (unknown), Karen Woods, Robert W. Wilkinson, Barry R. Davies, Sylvie M. Guichard	7
4	Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055) 2012 ·Cancer Research ·Sarah V. Holt, Armelle Logié, Barry R. Davies, Denis Alférez, Sarah Runswick, Sarah E. Fenton, Christine M. Chresta, Yi Gu, Jingchuan Zhang, Yi‐Long Wu, Robert W. Wilkinson, Sylvie M. Guichard, Paul D. Smith	70
5	The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models 2012 ·British Journal of Cancer ·Sarah V. Holt, Armelle Logié, Rajesh Odedra, Annabelle Heier, Simon P. Heaton, Denis Alférez, Barry R. Davies, Robert W. Wilkinson, Paul D. Smith	92
6	Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer 2012 ·Cancer Research ·Sylvie M. Guichard, Zoë Howard, Dan Heathcote, Mark J. Roth, Gareth Hughes, Jon Curwen, (unknown), Armelle Logié, Sarah V. Holt, Christine M. Chresta, Barry R. Davies, Karine Malagu, Marc Hummersone, (unknown), Stephen Green, Martin Pass	16
7	Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055 2011 ·Biochemical Society Transactions ·Gayle Marshall, Zoë Howard, Jonathan R. Dry, Sarah E. Fenton, Dan Heathcote, Neil Gray, (unknown), Armelle Logié, Sarah V. Holt, Paul D. Smith, Sylvie M. Guichard	28
8	The Development of an Immunohistochemical Method to Detect the Autophagy-Associated Protein LC3-II in Human Tumor Xenografts 2011 ·Toxicologic Pathology ·Sarah V. Holt, (unknown), Kevin J. Randall, Dominic I. James, John R. Foster, Robert W. Wilkinson	47
9	157 The mTOR kinase inhibitor AZD8055 induces cell death in Her2+ tumours partially or intrinsically resistant to ErbB2 inhibitors 2010 ·European Journal of Cancer Supplements ·Sarah V. Holt, Gayle Marshall, Armelle Logié, Zoë Howard, Sarah E. Fenton, Jonathan R. Dry, Dominic I. James, Edward M. Brown, Robert W. Wilkinson, Sylvie M. Guichard	1
10	Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours 2009 ·British Journal of Cancer ·Dahat A. Hussein, Sarah V. Holt, (unknown), Tetyana Klymenko, (unknown), Alison Hogg, EJ Estlin, Timothy H. Ward, Caroline Dive, Guy Makin	12
11	265 POSTER A MEK1/2 inhibitor, AZD6244 (ARRY-142886), shows beneficial effects when combined with standards of care or novel therapies – mechanistic characterisation suggests a role for apoptosis 2008 ·European Journal of Cancer Supplements ·Sarah V. Holt, Armelle Logié, Barry R. Davies, (unknown), (unknown), (unknown), D. Mark Hickinson, (unknown), Paul D. Smith, Robert W. Wilkinson	1
12	Downregulation of XIAP expression induces apoptosis and sensitizes a panel of pediatric tumor cells to cytotoxic agents 2007 ·Molecular Cancer Therapeutics ·Sarah V. Holt, (unknown), Jon P. Durkin, Caroline Dive, Guy Makin	1
13	Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic 2007 ·Cancer Treatment Reviews ·Emma Dean, Malcolm Ranson, Fiona Blackhall, Sarah V. Holt, Caroline Dive	37
14	Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint 2005 ·Journal of Cell Science ·Sarah V. Holt, M. Vergnolle, Deema Hussein, Marcin Woźniak, Viki Allan, Stephen S. Taylor	91
15	Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression 2004 ·Journal of Cell Science ·Victoria Johnson, (unknown), Sarah V. Holt, Deema Hussein, Stephen S. Taylor	271

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact